Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.42 |
| ▸ | LPL | P06858 | 12/20 | 0.42 |
| ▸ | TYR | P14679 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20875244 | 0.84 | LIPG (0.45) | LIPGLPLROCK1F11AAK1 | |
| SCHEMBL13642543 | 0.81 | LIPG (0.43) | LIPGLPLROCK1F11ESR2 | |
| SCHEMBL3226225 | 0.80 | LIPG (0.44) | LIPGLPLROCK1F11ESR2 | |
| SCHEMBL3233480 | 0.80 | LPL (0.44) | LIPGLPLROCK1F11ESR2 | |
| SCHEMBL16419564 | 0.79 | LIPG (0.49) | LIPGLPLROCK1F11HIF1A | |
| SCHEMBL23336941 | 0.77 | LPL (0.44) | LIPGLPLROCK1F11ESR2 | |
| SCHEMBL29418793 | 0.77 | LPL (0.44) | LIPGLPLROCK1F11ESR2 | |
| SCHEMBL17419172 | 0.76 | LPL (0.42) | LIPGLPLF11AAK1ESR2 | |
| Hydrochloric Acid SCHEMBL29418426 | 0.76 | LPL (0.42) | LIPGLPLROCK1F11ESR2 | |
| Hydrochloric Acid SCHEMBL25230858 | 0.76 | LPL (0.42) | LIPGLPLROCK1F11ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | LIPG 1952/4885LPL 1544/4885TYR 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.